T. Rowe Price Associates
XERS icon

T. Rowe Price Associates’s Xeris Biopharma Holdings XERS Stock Holding History

T. Rowe Price Associates’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
209,034
+35,571
+21% +$236K ﹤0.01% 2057
2025
Q4 		$1.36M Buy
173,463
+6,675
+4% +$52.5K ﹤0.01% 1949
2025
Q3 		$1.36M Buy
166,788
+13,517
+9% +$89.8K ﹤0.01% 1923
2025
Q2 		$716K Sell
153,271
-23,122
-13% -$106K ﹤0.01% 2131
2025
Q1 		$969K Buy
176,393
+5,911
+3% +$23.9K ﹤0.01% 1974
2024
Q4 		$578K Buy
170,482
+9,506
+6% +$30.6K ﹤0.01% 2230
2024
Q3 		$459K Buy
160,976
+30,008
+23% +$77.1K ﹤0.01% 2282
2024
Q2 		$295K Buy
130,968
+5,333
+4% +$10.7K ﹤0.01% 2420
2024
Q1 		$278K Buy
125,635
+10,632
+9% +$27.5K ﹤0.01% 2472
2023
Q4 		$271K Buy
115,003
+2,180
+2% +$4.02K ﹤0.01% 2424
2023
Q3 		$210K Buy
112,823
+2,404
+2% +$5.51K ﹤0.01% 2487
2023
Q2 		$290K Sell
110,419
-12,560
-10% -$32K ﹤0.01% 2381
2023
Q1 		$201K Hold
122,979
– – ﹤0.01% 2528
2022
Q4 		$164K Buy
122,979
+19,370
+19% +$27.3K ﹤0.01% 2590
2022
Q3 		$162K Buy
103,609
+66,975
+183% +$111K ﹤0.01% 2612
2022
Q2 		$56K Buy
36,634
+12,634
+53% +$26.7K ﹤0.01% 2843
2022
Q1 		$61K Buy
24,000
+11,300
+89% +$27.6K ﹤0.01% 2908
2021
Q4 		$37K Sell
12,700
-51,700
-80% -$112K ﹤0.01% 2939
2021
Q3 		$158K Buy
64,400
+7,500
+13% +$21.8K ﹤0.01% 2770
2021
Q2 		$232K Buy
56,900
+7,433
+15% +$28.4K ﹤0.01% 2672
2021
Q1 		$223K Buy
+49,467
New +$267K ﹤0.01% 2655

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's XERS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Xeris Biopharma Holdings (XERS) stake by 21% in Q1 2026, buying an estimated $236K and bringing the position to 209,034 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2057.

T. Rowe Price Associates first reported a position in XERS in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.36M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • T. Rowe Price Associates held 209,034 shares of Xeris Biopharma Holdings worth $1.21M as of Q1 2026.
  • T. Rowe Price Associates bought 35,571 Xeris Biopharma Holdings shares in Q1 2026, an estimated $236K.
  • Xeris Biopharma Holdings made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2057 holding.
  • T. Rowe Price Associates first reported a position in Xeris Biopharma Holdings in Q1 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Xeris Biopharma Holdings position peaked at $1.36M in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.